on-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent
Phase 4
Completed
- Conditions
- Health Condition 1: null- Advanced Renal Cell Carcinoma
- Registration Number
- CTRI/2009/091/000348
- Lead Sponsor
- Pfizer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Ages Eligible for Study: 18 Years to 75 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Sampling Method: Non-Probability Sample
Study Population
All patients with advanced renal cell cancer in the treatment naïve or cytokine refractory settings prescribed Sutent® will be eligible for the study.
Criteria
Inclusion Criteria:
Patients with advanced renal cell cancer, Treatment naïve or cytokine refractory
Exclusion Criteria
Patients presenting with a known hypersensitivity to sunitinib or its metabolites
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free SurvivalTimepoint: 1 year
- Secondary Outcome Measures
Name Time Method Management of all other adverse eventsTimepoint: 1 year;Management of skin & subcutaneous tissue related adverse eventsTimepoint: 1 year;Objective response rateTimepoint: 1 year;Safety and tolerabilityTimepoint: 1 year